Patents by Inventor Ziyang Zhong

Ziyang Zhong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11897930
    Abstract: Provided herein are an interleukin-2 polypeptide and a fusion protein thereof. Also provided herein are their pharmaceutical compositions and methods of use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: February 13, 2024
    Assignee: Anwita Biosciences, Inc.
    Inventors: Fan Ye, Eric Liao, Ella Li, Matthew Siegel, Jianing Huang, Ziyang Zhong
  • Publication number: 20230348549
    Abstract: Provided herein are a fusion protein comprising first and second cytokine domains, and a half-life extension domain; and a pharmaceutical composition thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
    Type: Application
    Filed: July 2, 2023
    Publication date: November 2, 2023
    Applicant: Anwita Biosciences, Inc.
    Inventors: Ziyang Zhong, Fan Ye, Matthew Siegel, Jianing Huang
  • Patent number: 11692020
    Abstract: Provided herein are a fusion protein comprising first and second cytokine domains, and a half-life extension domain; and a pharmaceutical composition thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: July 4, 2023
    Assignee: Anwita Biosciences, Inc.
    Inventors: Ziyang Zhong, Fan Ye, Matthew Siegel, Jianing Huang
  • Publication number: 20220195021
    Abstract: The present disclosure provides anti-albumin constructs each comprising an antialbumin single-domain antibody (sdAb) moiety. The anti-albumin constructs can further comprise a therapeutic agent, such as an antigen binding moiety or a cytokine. The present disclosure also provides methods of making and using the anti-albumin constructs.
    Type: Application
    Filed: February 21, 2020
    Publication date: June 23, 2022
    Inventors: Ziyang Zhong, Fan Ye, Matthew Siegel, Jianing Huang, Eric Liao, Ella Li
  • Publication number: 20220033454
    Abstract: Provided herein are a fusion protein comprising an interleukin-22 domain and an albumin binding domain, and a pharmaceutical composition thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of an inflammatory disease.
    Type: Application
    Filed: July 29, 2021
    Publication date: February 3, 2022
    Applicant: Anwita Biosciences, Inc.
    Inventors: Ziyang Zhong, Fan Ye, Jianing Huang, Matthew Siegel, Ji Wang
  • Publication number: 20210340208
    Abstract: Provided herein are an interleukin-2 polypeptide and a fusion protein thereof. Also provided herein are their pharmaceutical compositions and methods of use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
    Type: Application
    Filed: April 27, 2021
    Publication date: November 4, 2021
    Inventors: Fan Ye, Eric Liao, Ella Li, Matthew Siegel, Jianing Huang, Ziyang Zhong
  • Publication number: 20210340272
    Abstract: The present application relates to anti-mesothelin constructs (such as antimesothelin antibodies, cytokine fusion proteins that comprise the anti-mesothelin constructs), methods of preparing the anti-mesothelin constructs and methods of using the constructs (e.g., methods of treating a disease or condition). The present application also relates to a combination therapy for treating cancer that comprises administering anti-mesothelin agent and a cytokine (such as IL-21 or IL-15). Combination therapy may further comprises administration of an anti-Her2 agent.
    Type: Application
    Filed: June 17, 2019
    Publication date: November 4, 2021
    Inventors: Ziyang Zhong, Fan Ye, Matthew Siegel, Jianing Huang
  • Publication number: 20210230242
    Abstract: The present application provides fusion proteins that comprise a cytokine fused to an albumin binding moiety. The fusion proteins may further comprise an antigen binding moiety such as a therapeutic antibody. The present application also provides methods of making and using the fusion proteins. The present application also provides methods of treatment comprises administering a fusion protein comprising a cytokine fused to a half-life extending domain and a second agent.
    Type: Application
    Filed: June 17, 2019
    Publication date: July 29, 2021
    Inventors: Ziyang Zhong, Fan Ye, Matthew Siegel, Jianing Huang, Eric Liao, Ella Li
  • Publication number: 20210163565
    Abstract: Provided herein are a fusion protein comprising first and second cytokine domains, and a half-life extension domain; and a pharmaceutical composition thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
    Type: Application
    Filed: November 19, 2020
    Publication date: June 3, 2021
    Applicant: Anwita Biosciences, Inc.
    Inventors: Ziyang Zhong, Fan Ye, Matthew Siegel, Jianing Huang
  • Patent number: 8618085
    Abstract: Formulations of desoxyepothilones are stable before and after dilution into aqueous media.
    Type: Grant
    Filed: March 15, 2005
    Date of Patent: December 31, 2013
    Assignee: Koasn Biosciences Incorporated
    Inventors: Peter J. Licari, Ziyang Zhong, Indu Isaacs, John G. Augustine
  • Patent number: 7807430
    Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.
    Type: Grant
    Filed: March 3, 2008
    Date of Patent: October 5, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Stephen D Harrison, John A Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y Fang, Doris G Coit, Steve H Nguyen, Angelica Medina-Selby
  • Publication number: 20100137382
    Abstract: Formulations of desoxyepothilones are stable before and after dilution into aqueous media.
    Type: Application
    Filed: March 15, 2005
    Publication date: June 3, 2010
    Inventors: Peter Licari, Ziyang Zhong, Indu Isaacs, John Augustine
  • Publication number: 20080182313
    Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.
    Type: Application
    Filed: March 3, 2008
    Publication date: July 31, 2008
    Applicant: Novartis Vaccines and Diagonstics, Inc.
    Inventors: Stephen D. Harrison, John A. Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y. Fang, Doris G. Coit, Steve H. Nguyen, Angelica Medina-Selby
  • Patent number: 7361484
    Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.
    Type: Grant
    Filed: February 8, 2007
    Date of Patent: April 22, 2008
    Assignee: Chiron Corporation
    Inventors: Stephen D. Harrison, John A. Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y. Fang, Doris G. Coit, Steve H. Nguyen, Angelica Medina-Selby
  • Publication number: 20070249004
    Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.
    Type: Application
    Filed: February 8, 2007
    Publication date: October 25, 2007
    Applicant: Chiron Corporation
    Inventors: Stephen Harrison, John Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Fang, Doris Coit, Steve Nguyen, Angelica Medina-Selby
  • Publication number: 20070167422
    Abstract: A pharmaceutical formulation comprising (a) 17-allylamino-17-demethoxy-geldanamycin; (b) an ester of d-?-tocopheryl succinate and polyethylene glycol; and (c) a pharmaceutically acceptable, water-miscible organic solvent.
    Type: Application
    Filed: December 11, 2006
    Publication date: July 19, 2007
    Inventors: Kwok S. Yu, Ziyang Zhong
  • Patent number: 7195886
    Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.
    Type: Grant
    Filed: December 10, 2003
    Date of Patent: March 27, 2007
    Assignee: Chiron Corporation
    Inventors: Stephen D Harrison, John A Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y Fang, Doris G Coit, Steve H Nguyen, Angelica Medina-Selby
  • Patent number: 7135321
    Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.
    Type: Grant
    Filed: October 20, 2003
    Date of Patent: November 14, 2006
    Assignee: Chiron Corporation
    Inventors: Stephen D Harrison, John A Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y Fang, Doris G Coit, Steve H Nguyen, Angelica Medina-Selby
  • Publication number: 20060183160
    Abstract: The invention concerns a novel ?-secretase, a method of partially purifying this novel ?-secretase, and its use in assays to screen for potential drug candidates against Alzheimer's disease and other neurological diseases. The novel ?-secretase has an estimated molecular weight of about 32-39 kDa or 22-26 kDa in HEK293 cell membrane extracts and human brain samples, respectively, as calculated from radiation inactivation analysis, and has a pH optimum at about pH 6.5-7.0.
    Type: Application
    Filed: April 12, 2006
    Publication date: August 17, 2006
    Applicant: Scios, Inc.
    Inventors: Ziyang Zhong, Barbara Cordell, Diana Quon, Yu-Wang Liu, Qiang Xu, Frauke Schimmoller, Paul Hyslop, Edward Johnstone, Sheila Little, Stephen Queener, Tinggui Yin
  • Patent number: 7087399
    Abstract: The invention concerns a novel ?-secretase, a method of partially purifying this novel ?-secretase, and its use in assays to screen for potential drug candidates against Alzheimer's disease and other neurological diseases. The novel ?-secretase has an estimated molecular weight of about 32-39 kDa or 22-26 kDa in HEK293 cell membrane extracts and human brain samples, respectively, as calculated from radiation inactivation analysis, and has a pH optimum at about pH 6.5-7.0.
    Type: Grant
    Filed: May 9, 2000
    Date of Patent: August 8, 2006
    Assignee: Scios, Inc.
    Inventors: Ziyang Zhong, Barbara Cordell, Diana Hom Quon, Yu-Wang Liu, Qiang Xu, Frauke Schimmöller, Paul Andrew Hyslop, Edward Marion Johnstone, Sheila Parks Little, Steven Wyatt Queener, Tinggui Yin